[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alopecia-areata\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alopecia-areata":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,47,78,104,116,138,168,190,213,237,260,292,319,342,366,392,423,441,456,479,501,523,551,576,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054201","phase-3-a-study-to-evaluate-the-safety-and-effectiveness-of-upadacitinib-tablets-in-adult-and-adolescent-participants-with-severe-alopecia-areata-100054201",false,"NCT06012240","A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata","A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata","Up-AA","Inclusion Criteria:\n\n* Adult individuals must be \\\u003C 64 years old at Baseline Visit. Where permitted outside United States (US)\u002FEuropean Union (EU), adolescent individuals who are at least 12 years old at Screening may participate in Study 1 and Study 2. Adolescent individuals in the US who are at least 12 years old at Screening may participate in Study 4.\n* Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score \\>= 50 scalp hair loss at Screening and Baseline.\n* Severe AA with no spontaneous scalp hair regrowth over the past 6 months.\n* Current episode of AA of less than 8 years.\n\nExclusion Criteria:\n\n* Current diagnosis of primarily diffuse type of AA.\n* Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium.\n* Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.","ALL","12 Years","63 Years",{"count":22,"type":23},1500,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA.\n\nUpadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide.\n\nParticipants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[29],"Alopecia Areata",[29,31,32,33],"Upadacitinib","Rinvoq","ABT-494","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2023-10-11",{"date":42,"type":23},"2030-04",{"name":44,"class":45},"AbbVie","INDUSTRY",281,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100640974","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-japanese-adults-with-severe-alopecia-areata-100640974","NCT07617597","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period","THRIVE-AAJP","Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.\n* Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.\n* SALT score of 50 or more at both Screening and Baseline.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.\n* Treatment with biologics within 6 months prior to Screening.\n* Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.\n* History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.\n* Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.","18 Years","65 Years",{"count":58,"type":23},78,[26],"This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.",[29],[63,64,65,66,67],"alopecia areata","severe alopecia areata","hair loss","deuruxolitinib","JAK inhibitor","2026-06-30",{"date":70,"type":38},"2026-07-02",{"date":72,"type":38},"2026-06-19",{"date":74,"type":23},"2028-09",{"name":76,"class":45},"Sun Pharma Japan Limited",18,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100573540","phase-2-evaluation-of-microbiota-transplant-therapy-in-patients-with-alopecia-areata-100573540","NCT06747611","Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata","Inclusion Criteria:\n\n* Patients 18 to 75 years of age with moderate to severe alopecia areata (SALT score \\>30%).\n* Patients with a diagnosis of patch type alopecia areata, totalis, or universalis..\n* Duration of hair loss \\>=3 months..\n* No evidence of active, ongoing regrowth present at baseline.\n* Females of childbearing potential must have a negative urine or serum pregnancy test at screening and immediately prior to MTT.\n* Females of childbearing potential must agree to use an effective form of contraception from 14 days prior to study antibiotics through at least 30 days after MTT. Acceptable forms of contraception include oral or intramuscular contraceptives, intrauterine devices, surgical sterilization.\n* Participants are not enrolled in another clinical study.\n* If undergoing treatment with a JAK inhibitor, participant is willing to discontinue treatment for 1 month prior to enrollment and throughout the duration of the study.\n\nExclusion Criteria:\n\n* Active gastrointestinal infection at time of enrollment.\n* Having been administered antibiotics in the last 48 hours.\n* Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to treatment..\n* Requires continued antibiotic use\n* Allergy to study antibiotics (vancomycin, neomycin).\n* Known or suspected severe gastrointestinal dysmotility disorder, e.g., gastroparesis, pseudo-obstruction, scleroderma with gastrointestinal involvement\n* Ileus or small bowel obstruction.\n* Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy.\n* History of total colectomy.\n* Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy.\n* Unable or unwilling to comply with protocol requirements.\n* Expected life expectancy \\< 6 months.\n* Previous MTT or microbiome-based products at any time excluding this study.\n* History of severe anaphylactic or anaphylactoid food allergy.\n* Solid organ transplant recipients 90 days post-transplant or on active treatment for rejection.\n* A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.\n* History of or existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis and patients with evidence of infection or skin cancer in the treated areas.\n* Patients in whom the diagnosis of alopecia areata is questionable.\n* Patients in whom regrowth is present\u002Fevident at baseline in the areas to be treated.\n* Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma of the skin) which in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.\n* Patients unwilling or unable to discontinue treatments known to affect hair regrowth in alopecia areata.\n* Patients who have been treated with intralesional steroids, systemic steroids, anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil, JAK inhibitors or other medication which in the opinion of the investigator may affect hair regrowth, within one month of the baseline visit..\n* Patients determined by the investigator to have extreme diets..\n* Pregnant and breastfeeding females..","75 Years",{"count":86,"type":23},40,[88],"PHASE2","Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the United States alone, including males and females across all ethnic groups, with a lifetime risk of 2.1%. Autoimmunity develops against the hair follicle, resulting in non-scarring hair loss that may begin as patches that can coalesce and progress to cover the entire scalp (alopecia totalis) or eventually the entire body (alopecia universalis). In AA, there is no permanent destruction of the hair follicle, and regrowth remains possible. Treatment options for AA include intralesional steroids, topical anthralin, allergic contact dermatitis with diphencyprone (DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE), and recently janus kinase ( JAK) inhibitors. Despite the recent approval of JAKs for the treatment of extensive alopecia areata, some patients are treatment resistant, suffer relapses, or cannot take an oral immunosuppressive medication.\n\nThis study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.",[29,91,92],"Alopecia Totalis","Alopecia Universalis","2026-06-25",{"date":95,"type":38},"2026-06-26",{"date":97,"type":38},"2025-08-21",{"date":99,"type":23},"2028-03-15",{"name":101,"class":102},"University of Minnesota","OTHER",1,{"id":105,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":27,"conditions":108,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":114,"locationsCount":115},"100517030",{"count":22,"type":23},[26],[29],[29,31,32,33],{"date":111,"type":38},"2026-06-29",{"date":40,"type":38},{"date":42,"type":23},{"name":44,"class":45},275,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100633924","phase-2-a-study-of-ly4005130-in-adult-participants-with-severe-alopecia-areata-hair-loss-100633924","NCT07533006","A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)","A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata","Inclusion Criteria:\n\n* Have severe Alopecia Areata (AA) that meets all of the following criteria:\n\n  * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score\n  * The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years\n  * No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months\n  * Agree not to use any AA treatments during the study\n\nExclusion Criteria:\n\n* Primarily \"diffuse\" type of AA (characterized by diffuse hair shedding)\n* Are currently experiencing other forms of alopecia\n* Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and\u002For frequent use of systemic immunosuppressants that may interfere with participation in the study\n* Have received oral JAK Inhibitors in the past\n* Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness","50 Years",{"count":125,"type":23},60,[88],"The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study drug will be administered intravenously (IV) (into a vein in the arm).\n\nThe study will last approximately 48 weeks, including screening.",[29],{"date":130,"type":38},"2026-06-23",{"date":132,"type":38},"2026-04-14",{"date":134,"type":23},"2027-10",{"name":136,"class":45},"Eli Lilly and Company",30,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":18,"minAge":19,"maxAge":84,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":103},"100469899","phase-2-evaluate-the-efficacy-and-safety-of-ruxolitinib-on-hair-regrowth-in-patients-with-autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy-apeced-associated-alopecia-areata-100469899","NCT05398809","Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","* INCLUSION CRITERIA:\n\nFor participants with APECED-associated AA:\n\n1. Participant must be able to understand and provide informed consent.\n2. Aged \\>=12 to \\\u003C=75 years.\n3. Patients with APECED (genetic or clinical diagnosis) and severe AA (defined as having \\>=50% total scalp loss at screening per the SALT score).\n4. Duration of hair loss greater than 6 months.\n5. No present evidence of hair regrowth.\n6. Is na(SqrRoot) ve or unresponsive to other treatments for AA.\n7. No treatment for alopecia in the past 2 months prior to study enrollment.\n8. Willingness to use valacyclovir prophylaxis for the prevention of herpes viral reactivation.\n9. Vaccinations should be up to date in agreement with current CDC immunization guidelines prior to start of ruxolitinib.\n10. Proficient in written English.\n11. Participants who can get pregnant or impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at screening until 12 weeks after the last dose. Highly effective contraceptive measures include:\n\n    1. Stable use of combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) starting 1 month prior to screening.\n    2. Intrauterine device; intrauterine hormone-releasing system.\n    3. Two barrier methods (eg, condom with spermicide, diaphragm with spermicide, or cervical cap and spermicide). Internal and external condoms may not be used together.\n    4. Bilateral tubal ligation.\n\nPeriodic abstinence (calendar, symptothermal, and post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception.\n\nFor family members or household contacts:\n\n1. Aged \\>=18 years.\n2. Lives with the participant.\n3. Proficient in written English.\n\nEXCLUSION CRITERIA:\n\nFor participants with APECED-associated AA:\n\n1. Known history of hypersensitivity to ruxolitinib or other JAK inhibitors.\n2. History of or active skin disease on the scalp other than AA, such as psoriasis or seborrheic dermatitis.\n3. Diagnosis of AA is in question or the pattern of hair loss is such that quantification of hair loss and assessment of regrowth is difficult, eg, patients with androgenic alopecia.\n4. Treated within the last 2 months with intralesional steroids, systemic steroids, anthralin, squaric acid, diphenylcyclopropenone, tacrolimus, minoxidil, or other medication that, in the opinion of the investigator, may affect hair regrowth.\n5. Current or recent use of any investigational drug (within 3 months or 5 half-lives, whichever is longer, prior to screening).\n6. Scheduled to participate in another clinical study involving an investigational drug during the course of this study.\n7. Use of systemic immunosuppressive or immune-modulating agents within 3 months prior to screening, except systemic steroids 10 mg of prednisone equivalent per day.\n8. Current use of systemic steroids with daily dose \\>10 mg of prednisone equivalent for any reason or steroid burst for \\>3 days within 1 month of screening.\n9. History of alcohol or drug abuse within 6 months prior to screening.\n10. Presence of one or more of the following clinically significant laboratory abnormalities:\n\n    1. Serum ALT\\>=3 times upper limit of normal (ULN).\n    2. Serum total bilirubin \\>=2 times ULN.\n    3. ANC\\\u003C=1000 cells\u002Fmicroliter.\n    4. Hemoglobin \\\u003C=9.0 g\u002FdL.\n    5. Platelet count \\\u003C=100,000\u002Fmicroliter.\n    6. Serum creatinine \\>=2 times ULN.\n11. Planned or anticipated major surgical procedure during the study.\n12. Plans to receive any live vaccines within 1 month of the anticipated first dose of ruxolitinib.\n13. Known or suspected immunodeficiency disorder besides APECED.\n14. History of untreated invasive opportunistic infections (eg, tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, aspergillosis) despite infection resolution or otherwise recurrent infections of\n\n    abnormal frequency or prolonged infections suggesting an immune-compromised status as judged by the investigator.\n15. Untreated latent tuberculosis infection.\n16. Infection with HIV.\n17. Untreated infection with hepatitis B or C.\n18. History of serious bacterial infection within the last 3 months prior to screening, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis).\n19. History of unprovoked DVT, PE, arterial thrombosis, or other thrombotic events.\n20. History of stroke, heart attack, or heart failure.\n21. History of herpes zoster or cytomegalovirus infection that resolved within 2 months prior to screening.\n22. History of basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix, unless the participant is in remission and curative therapy was completed at least 12 months prior to screening.\n23. History of other malignancies, unless the participant is in remission and curative therapy was completed at least 5 years prior to screening.\n24. Planned or anticipated use of any prohibited medications and procedures during the study.\n25. Current pregnancy or breastfeeding.\n26. Past or current medical problems or findings from physical examination, EKG, or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant s ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n\nThere are no exclusion criteria for family members or household contacts.",true,{"count":147,"type":23},70,[88],"Background:\n\nAutoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA.\n\nObjective:\n\nTo see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body.\n\nEligibility:\n\nPeople aged 12 to 65 years with APECED and severe AA.\n\nDesign:\n\nParticipants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital.\n\nThe first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life.\n\nParticipants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen.\n\nSome tests may be repeated in subsequent in-person visits.\n\nIn telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.",[151,29],"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)",[153,154,155,156,157],"Aps-1","Aire","Jak","Autiommunity","Hair Loss","2026-06-18",{"date":160,"type":38},"2026-06-22",{"date":162,"type":38},"2023-01-18",{"date":164,"type":23},"2027-12-01",{"name":166,"class":167},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100481652","phase-2-regeneron-aa-multicenter-dupilumab-100481652","NCT05551793","Regeneron AA Multicenter (Dupilumab)","Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and\u002For High IgE","INCLUSION CRITERIA:\n\n* Male or female subjects who are at least 18 years old at the time of informed consent.\n* Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.\n* Subject is able to adhere to the study visit schedule and other protocol requirements.\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:\n\n  * Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy, OR;\n  * Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural \\[animal\\] membrane \\[for example, polyurethane\\]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.\n* If subject is a female of non-childbearing potential, she must have documented history of infertility, be in a menopausal state for one year, or had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.\n* Subject has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score; OR subject has ≥ 95% loss of scalp hair for enrollment as AA totalis (AT) or universalis (AU) subtypes.\n* Subject has a screening IgE \\> 200 and\u002For personal and\u002For familial history of atopy.\n* Subjects must meet the following laboratory criteria:\n\n  * White blood cell count ≥ 3000\u002Fmm3 (≥ 3.0 x 109\u002FL) and \\\u003C 14,000\u002Fmm3 (≤ 14 x 109\u002FL).\n  * Platelet count ≥ 100,000\u002FμL (≥ 100 x 109\u002FL).\n  * Serum creatinine ≤ 1.5 mg\u002FdL (≤ 132.6 μmol\u002FL).\n  * AST (SGOT) and ALT (SGPT) ≤ 2 x upper limit of normal (ULN). If the initial test shows ALT or AST \\> 2 times the ULN, one repeat test is allowed during the Screening Phase.\n  * Total bilirubin ≤ 2 mg\u002FdL (34 μmol\u002FL). If the initial test shows total bilirubin \\> 2 mg\u002FdL (34 μmol\u002FL), one repeat test is allowed during the Screening Phase.\n  * Hemoglobin ≥ 10 g\u002FdL (≥ 6.2 mmol\u002FL).\n* Subject is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nEXCLUSION CRITERIA:\n\nThe presence of any of the following will exclude a subject from enrollment:\n\n* Subject is pregnant or breastfeeding.\n* Subject's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V).\n* Subject has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss.\n* Severe, uncontrolled asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations.\n* Subject has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics\n* Subject with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator.\n* Subject has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n* Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology or active or untreated latent tuberculosis at the time of screening for subjects determined by the investigators to be at high-risk for this disease.\n* Subject has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Subject has received a live attenuated vaccine ≤ 30 days prior to study randomization.\n* Subject has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints.\n* Subject has any other medical or psychological condition that, in the opinion of the investigator, may present additional unreasonable risks as a result of their participation in the study and\u002For interfere with clinic visits and necessary study assessments.\n* History of adverse systemic or allergic reactions to any component of the study drug.\n* Severe, untreated asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, or ultraviolet (UV) phototherapy with\u002Fwithout Psoralen Ultraviolet A (PUVA) therapy within 4 weeks prior to randomization.\n* Use of an oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, or investigational oral JAK Inhibitors) within 12 weeks prior to the Baseline visit.\n* Subject has been previously treated with dupiliumab.\n* Subject has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus within 1 week before the Baseline visit.\n* Subject currently uses or plans to use anti-retroviral therapy at any time during the study.",{"count":176,"type":23},76,[88],"This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and\u002For have personal and\u002For familial history of atopy.\n\nSubjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).",[29],"2026-06-15",{"date":182,"type":38},"2026-06-17",{"date":184,"type":38},"2023-04-10",{"date":186,"type":23},"2028-10-31",{"name":188,"class":102},"Emma Guttman",3,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100556899","characterization-and-clinical-outcomes-of-aa-patients-treated-with-ritlecitinib-100556899","NCT06531109","Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib","PRESTO - Characterization and Clinical Outcomes of Alopecia Aerata (AA) Patients Treated With Ritlecitinib in a Real-world (RW) Cohort: A Multinational, Prospective Observational Study.","PRESTO","Inclusion Criteria:\n\n1. Male and female patients aged \\>12 years at baseline.\n2. Patients with diagnosis of alopecia areata confirmed by a certified dermatologist, who are prescribed ritlecitinib as per the product label independently of the decision to enroll a patient in this study.\n3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Following receipt of oral and written information about the trial, the adolescent (depending on local institutional review board\u002Findependent ethics committee requirements) must provide assent, and one or both (according to local regulations) parents or guardians of the child must provide signed informed consent before any study-related activity is carried out.\n4. Patients, who in the opinion of the investigator, are willing and able to comply with regular clinic visits as per standard practice at the site and agree to complete PRO questionnaires and other patient completed questions.\n\nExclusion Criteria:\n\n1. Diagnosed with other types of alopecia or other diseases that can cause hair loss (including, but not limited to known androgenetic alopecia, traction and scarring alopecia, telogen effluvium).\n2. Diagnosed with other scalp diseases that may impact AA assessment (e.g., scalp psoriasis, dermatitis, etc.) or other active systemic diseases that may cause hair loss (e.g., lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc.). that could interfere with assessment of hair loss\u002Fregrowth.\n3. Patients previously treated with ritlecitinib or other JAK inhibitors.\n4. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.",{"count":199,"type":23},850,"OBSERVATIONAL","Alopecia areata (AA) is a chronic relapsing autoimmune disease characterized by nonscarring hair loss affecting children, adolescents, and adults across all ages, races, and genders. AA primarily affects the scalp; however, it also can affect nails, eyelashes, eyebrows, and other hair follicles on the patient's body. The 3 main types of AA are:\n\n* Patchy alopecia (PA), as seen in 90% of clinical diagnoses\n* Alopecia totalis (AT), that affects all scalp hair\n* Alopecia universalis (AU), involving all scalp, face, and body hair Dermatologist preferences for utility and order of skin-directed therapies to treat AA vary widely, with treatment choices based on various factors such as patients' age, disease duration and severity (Meah et al., 2020).\n\nRitlecitinib is a bioavailable small molecule that irreversibly binds to Janus kinase-3 (JAK3) and Tyrosine kinase Expressed in the hepatocellular Carcinoma kinase family (TEC). Ritlecitinib 50 mg once daily was approved by the FDA 23 June 2023 and EMA 20 July 2023 for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In Japan, ritlecitinib was approved on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Additional countries have since approved ritlecitinib. Those approvals are based on the results of the ritlecitinib pivotal phase 2b\u002F3 study (ALLEGRO 2b\u002F3) which examined efficacy and safety of ritlecitinib in AA patients globally.\n\nDespite positive results from the ALLEGRO program, there is still lack of evidence on ritlecitinib patients' characteristics and clinical outcomes in routine clinical practice. The investigators will evaluate patient and disease characteristics, treatment patterns, and clinical and patient-reported outcomes among patients with AA who are receiving ritlecitinib.\n\nThe aim of this study is to measure effectiveness of ritlecitinib in a real-world setting. Ritlecitinib will be prescribed to patients according to the approved product label. Treatment will be guided by clinical judgement of the treating physician ie, study investigators, according to standard of care, independently of this study.",[29],"2026-05-28",{"date":205,"type":38},"2026-06-01",{"date":207,"type":38},"2024-08-07",{"date":209,"type":23},"2028-03-31",{"name":211,"class":45},"Pfizer",58,{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":220,"targetDuration":4,"studyType":24,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":103},"100616896","phase-2-a-study-of-lad603-in-adults-with-alopecia-areata-100616896","NCT07311564","A Study of LAD603 in Adults With Alopecia Areata","A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata","Inclusion Criteria:\n\n* Participant is a male or female between 18 and 65 years old at the time of signing the informed consent.\n* Severe to very severe AA criteria:\n\n  1. Greater than or equal to (\\>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits.\n  2. Current episode of hair loss lasting at least 6 months and not exceeding 7 years.\n* Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,\n\nExclusion Criteria:\n\nAA, Skin Specific, and Other Inflammatory Diseases\n\n* Participants have other types of alopecia (including but not limited to traction, scarring alopecia).\n* Participants with \"diffuse\" type AA.\n* Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.\n\nOther Medical Conditions\n\n* Participant has previous severe adverse reaction to subcutaneously administered medication.\n* Participant has any of the following liver safety laboratory results at Screening\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to (\\>=) 2.5 × upper limit of normal (ULN)\n  2. Total bilirubin (TBL) \\>=1.5 × ULN (TBL \\>=3 × ULN in participants with Gilbert's syndrome)\n  3. Alkaline phosphatase (ALP) \\>=1.5 × ULN\n\n     Prior\u002FConcomitant Therapy\n* Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.",{"count":221,"type":23},136,[88],"The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.",[29],[157,226,227],"Hypotrichosis","Alopecia","2026-05-19",{"date":230,"type":38},"2026-05-20",{"date":232,"type":38},"2025-12-17",{"date":234,"type":23},"2027-11-21",{"name":236,"class":45},"Almirall, S.A.",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":244,"maxAge":56,"enrollmentInfo":245,"targetDuration":4,"studyType":24,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100524139","phase-2-safety-and-efficacy-of-oral-nxc-736-in-adult-participants-with-moderate-and-severe-alopecia-areata-100524139","NCT06104839","Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata","Inclusion Criteria:\n\n* Men or women between ≥19 and ≤65 years of age at the time of informed consent\n* Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \\\u003C 95% at Screening and Day 1\u002FBaseline\n* Current episode of hair loss for ≥6 months but \\\u003C8 years\n* Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator\n* Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study\n\nExclusion Criteria:\n\n* Participants with the following medical history confirmed during screening:\n\n  * ohter Types of alopecia other than alopecia areata (such as cicatricial\u002Fscarring alopecia \\[including central centrifugal cicatricial alopecia\\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)\n* Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment\n* Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors","19 Years",{"count":246,"type":23},73,[88],"The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).",[29],"2026-04-09",{"date":252,"type":38},"2026-04-13",{"date":254,"type":38},"2024-09-01",{"date":256,"type":23},"2027-01-31",{"name":258,"class":45},"NEXTGEN Bioscience",2,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":123,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":270,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":281,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100628307","phase-4-topical-methotrexate-vs-minoxidil-for-localized-alopecia-areata-100628307","NCT07459933","Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","Comparative Study Between Topical Methotrexate 1% Gel and Minoxidil 5% Spray in the Treatment of Localized Alopecia Areata: A Randomized Controlled Trial","MTX-MNX-AA","Inclusion Criteria:\n\nPatients aged 18 to 50 years.\n\nPatients of either gender.\n\n* Patients diagnosed with localized alopecia areata, defined as one or more smooth, well-circumscribed patches of non-scarring hair loss on the scalp with less than 25% scalp involvement, assessed using the Severity of Alopecia Tool (SALT) score.\n* Patients not previously treated with topical methotrexate or minoxidil for alopecia areata.\n* Patients willing to provide written informed consent and comply with follow-up visits.\n\nExclusion Criteria:\n\n* Patients with other types of alopecia, including androgenetic alopecia, telogen effluvium, or scarring alopecia.\n* Patients with systemic diseases that may influence hair growth or treatment response, such as uncontrolled thyroid disease, uncontrolled diabetes mellitus, or autoimmune connective tissue disorders.\n* Pregnant or lactating women.\n* Patients who have used topical or systemic treatment for alopecia areata within the past 3 months.\n* Patients with known hypersensitivity or allergy to methotrexate or minoxidil.",{"count":269,"type":23},268,[271],"PHASE4","Alopecia areata is an autoimmune disorder characterized by well-defined, non-scarring patches of hair loss on the scalp and other hair-bearing areas. Although several treatment options are available, there is no universally accepted standard therapy, and treatment responses vary widely among patients.\n\nMinoxidil is commonly used for hair regrowth due to its ability to stimulate hair follicles and prolong the anagen phase of the hair cycle. Methotrexate, an immunosuppressive agent traditionally used in inflammatory and autoimmune diseases, has also been explored as a potential treatment for alopecia areata because of its ability to suppress immune-mediated follicular damage.\n\nThis randomized controlled trial aims to compare the efficacy and safety of topical methotrexate 1% gel versus minoxidil 5% spray in patients with localized alopecia areata. Eligible participants will be randomly assigned to receive either topical methotrexate gel or minoxidil spray and will be followed for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score. The findings of this study may help identify an effective therapeutic option for patients with localized alopecia areata and contribute to improving clinical management strategies for this condition.",[29],[275,276,277,278,279,280],"Localized Alopecia Areata","Topical Methotrexate","Minoxidil 5%","Hair Regrowth","Autoimmune Hair Loss","SALT Score","NOT_YET_RECRUITING","2026-03-04",{"date":284,"type":38},"2026-03-10",{"date":286,"type":23},"2026-03-15",{"date":288,"type":23},"2026-09-15",{"name":290,"class":291},"Jinnah Postgraduate Medical Centre","OTHER_GOV",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":123,"enrollmentInfo":300,"targetDuration":4,"studyType":24,"phases":301,"briefSummary":302,"conditions":303,"keywords":304,"overallStatus":281,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100627792","phase-4-comparison-of-topical-calcipotriol-and-intralesional-steroids-in-alopecia-areata-100627792","NCT07453238","Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","Comparison of Topical Calcipotriol Versus Intralesional Corticosteroids in the Treatment of Alopecia Areata: A Randomized Controlled Trial","CALISTA-AA","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Clinically diagnosed patchy alopecia areata\n* Scalp involvement of less than 50% (SALT score \\\u003C50%)\n* No topical or systemic treatment for alopecia areata within the previous 3 months\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diffuse alopecia areata or scarring alopecia\n* Presence of other autoimmune diseases or significant systemic illness\n* Known hypersensitivity to calcipotriol or corticosteroids\n* Pregnant or lactating women\n* Current use of immunosuppressive therapy\n* Unwillingness to participate or provide informed consent",{"count":125,"type":23},[271],"This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss and can significantly affect quality of life. Intralesional corticosteroids are commonly used as first-line therapy; however, response rates vary and treatment may be associated with discomfort and local adverse effects.\n\nSixty adult patients with patchy alopecia areata involving less than 50% of the scalp were randomly assigned to receive either topical calcipotriol or intralesional corticosteroid injections for 12 weeks. Participants were evaluated at four-week intervals. Treatment response was assessed using the Severity of Alopecia Tool (SALT) score and percentage improvement from baseline.\n\nThe primary objective is to compare reduction in SALT score between the two treatment groups. Secondary outcomes include overall treatment efficacy and safety. The findings aim to determine whether topical calcipotriol provides superior or comparable clinical benefit to intralesional corticosteroids in patients with alopecia areata.",[29],[29,305,306,307,278,308,309],"Topical Calcipotriol","Intralesional Corticosteroids","Randomized Controlled Trial","Vitamin D Analog","Patchy Alopecia","2026-03-02",{"date":312,"type":38},"2026-03-05",{"date":314,"type":23},"2026-04-01",{"date":316,"type":23},"2026-10-01",{"name":318,"class":291},"Hayat Abad Medical Complex, Peshawar",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100505836","phase-2-dupilumab-in-the-treatment-of-pediatric-alopecia-areata-100505836","NCT05866562","Dupilumab in the Treatment of Pediatric Alopecia Areata","PEDAL","Inclusion Criteria:\n\n* Male or female participants who are at least 6 years old and under 18 years old, who can provide assent (if appropriate), and for whom signed informed consent can be provided by parent or legal guardian prior to participation in any study assessments or procedures\n\n  \\-- Participant is able to adhere to the study visit schedule and other protocol requirements.\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:\n\n  * Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR\n  * Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural \\[animal\\] membrane \\[for example, polyurethane\\]);\n* Participant has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score.\n* Participant has a screening IgE ≥ 200 and\u002For personal and\u002For familial history of atopy (including asthma, atopic dermatitis, allergic rhinitis, food allergy, or eosinophilic esophagitis)\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n* Participant is pregnant or breastfeeding.\n* Participant's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V).\n* Participant has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss.\n* Severe, uncontrolled asthma (having 2 or exacerbations in the last 12 months that require systemic steroids and\u002For hospitalization) or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic medications.\n* Participant has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics\n* Participant with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator.\n* Participant has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n* Known active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening for subjects determined by the investigators to be at high-risk for this disease.\n* Participant has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Participant has received a live attenuated vaccine ≤ 28 days prior to study randomization.\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n* History of adverse systemic or allergic reactions to any component of the study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, ritlecitinib, or investigational oral JAK Inhibitors) or ultraviolet (UV) phototherapy with\u002Fwithout Psoralen Ultraviolet A (PUVA) therapy, within 4 weeks prior to the Week 0\u002FBaseline visit\n* Participant has been previously treated with dupilumab\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus within 1 week before the Baseline visit.","6 Years","17 Years",{"count":176,"type":23},[88],"This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and\u002For have personal and\u002For familial history of atopy.\n\nStudy participation will be up to 124 weeks, consisting of: a screening period of up to 4 weeks; a 48-week placebo-controlled period; a 48-week open-label extension period; followed by a 24-week follow-up period.",[29],"2026-02-19",{"date":334,"type":38},"2026-02-20",{"date":336,"type":38},"2024-07-11",{"date":338,"type":23},"2029-04-30",{"name":340,"class":102},"Icahn School of Medicine at Mount Sinai",5,{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":365},"100603434","a-real-world-study-to-globally-assess-disease-burden-in-adolescent-and-adult-participants-with-alopecia-areata-vitiligo-or-hidradenitis-suppurativa-100603434","NCT07136467","A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa","Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)","MEASUREAAVitHS","Inclusion Criteria:\n\n* Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)\n* Participants Ability to understand study questionnaires, with caregiver support as required for adolescents\n\nExclusion Criteria:\n\n* Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)\n* Unable or unwilling to comply with study requirements and PRO collection",{"count":351,"type":23},2795,"This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.",[354,29,355],"Non-Segmental Vitiligo (NSV)","Hidradenitis Suppurativa",[354,29,355],"2026-02-12",{"date":359,"type":38},"2026-02-13",{"date":361,"type":38},"2025-09-02",{"date":363,"type":23},"2027-08",{"name":44,"class":45},116,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":281,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100624174","phase-4-tofacitinib-vs-methotrexate-for-severe-alopecia-areata-tofa-mtx-aa-100624174","NCT07406204","Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial","TOFA-MTX-AA","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nClinical diagnosis of severe alopecia areata, alopecia totalis, or alopecia universalis (as per protocol\u002Foperational definition), confirmed by a consultant dermatologist.\n\nEither sex.\n\nAble and willing to provide written informed consent.\n\nExclusion Criteria:\n\nCurrently receiving or recently used any systemic treatment intended for hair regrowth for alopecia areata (e.g., systemic corticosteroids, immunosuppressants, JAK inhibitors).\n\nPregnant women.\n\nHistory or clinical evidence of renal, hepatic, or pulmonary disease.\n\nAny condition that, in the investigator's judgment, makes participation unsafe or interferes with adherence to the study protocol.","60 Years",{"count":58,"type":23},[271],"This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair). Alopecia areata is an autoimmune condition that can cause significant hair loss and emotional distress.\n\nAdults aged 18 to 60 years with severe disease will be enrolled at the Department of Dermatology, MTI-Hayatabad Medical Complex, Peshawar, after ethical approval and written informed consent. Participants will be randomly assigned to receive either tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks.\n\nThe main outcome will be improvement in hair loss measured by the Severity of Alopecia Tool (SALT) score. Treatment will be considered effective if there is more than 50% improvement in SALT score from baseline at the end of 12 weeks. Safety will be monitored during follow-up visits. The findings may help guide treatment decisions for severe alopecia areata in our local population.",[29,379,92],"Alopecia Totalis (AT)",[381,382,383,384,279],"Tofacitinib","Methotrexate","Janus Kinase Inhibitor","Severe Alopecia Areata","2026-02-05",{"date":357,"type":38},{"date":388,"type":23},"2026-02-15",{"date":390,"type":23},"2026-08-15",{"name":318,"class":291},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":400,"targetDuration":4,"studyType":24,"phases":402,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":103},"100612239","pallas-laser-for-skin-diseases-100612239","NCT07250997","PALLAS Laser for Skin Diseases","Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light","PALLAS-UV","Inclusion Criteria:\n\n1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,\n2. a skin condition that is expected to respond well to targeted UVB treatment,\n3. a signed consent form.\n\nExclusion Criteria:\n\n1. Patient under 18 years of age,\n2. pregnancy\n3. epilepsy,\n4. fever, infectious diseases,\n5. the patient is within one month or currently enrolled in another clinical trial.",{"count":401,"type":23},50,[403],"NA","The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).\n\nThe secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases.\n\nThe patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial.\n\nThe treatment takes approximately 10 minutes per session, and can last up to 3 months per patient.\n\nPhotographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month.\n\nAt the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.",[406,407,29,408],"Vitiligo Vulgaris","Psoriasis","Atopic Dermatitis",[410,411,412,413,63,414],"UVB laser treatment","PALLAS laser","vitiligo","psoriasis","atopic dermatitis",{"date":416,"type":38},"2026-02-06",{"date":418,"type":38},"2025-12-10",{"date":420,"type":23},"2026-12-31",{"name":422,"class":102},"Szeged University",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":327,"enrollmentInfo":429,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":103},"100559295","corevitas-international-adolescent-alopecia-areata-aa-drug-safety-and-effectiveness-registry-100559295","NCT06562270","CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry","Inclusion Criteria:\n\nTo be eligible to participate in this registry, an individual must meet all the following criteria:\n\n1. Has ever been diagnosed with severe AA by a dermatologist or a qualified dermatology provider.\n2. Is 12-17 years of age at the time of enrollment.\n3. Is willing to provide consent\u002Fassent for participation in the registry.\n4. Has been prescribed a new commercially available advanced therapy and\u002For conventional systemic therapy for the treatment of severe AA in adolescents in the context of routine clinical care that is consistent with local prescribing guidelines and\u002For regulations for the country where the site is located.\n\nA new therapy is a medication that the subject has never taken before.\n\n1. At the time of registry enrollment OR\n2. Within 6 months prior to registry enrollment In the opinion of the treating provider, is deemed a candidate for treatment with a commercially available advanced therapy and\u002For conventional systemic therapy for the treatment of severe AA in adolescents but has not received nor is planning to initiate treatment at the time of registry enrollment.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the registry:\n\n1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.\n2. Is unwilling or unable to provide standing height measurements.",{"count":22,"type":23},"Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines\u002Fregulations in the country where the participating registry site is located.",[29],{"date":433,"type":38},"2026-02-09",{"date":435,"type":38},"2024-03-07",{"date":437,"type":23},"2099-12-31",{"name":439,"class":440},"CorEvitas","NETWORK",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":455,"locationsCount":103},"100496527","corevitas-alopecia-areata-aa-safety-and-effectiveness-registry-100496527","NCT05745389","CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry","Inclusion Criteria:\n\n* A subject must meet all the following criteria to participate in the registry:\n\n  1. Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner.\n  2. Is at least 18 years of age or older.\n  3. Is willing to provide Personal Information.\n  4. Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment.\n\nExclusion Criteria:\n\n* Any of the following would exclude the subject from participating in the registry:\n\n  1. Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note:\n\nConcurrent participation in another observational registry or open-label Phase 3b\u002F4 trial is allowed.",{"count":448,"type":23},5000,"Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.",[29],{"date":433,"type":38},{"date":453,"type":38},"2022-10-25",{"date":437,"type":23},{"name":439,"class":440},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":103},"100611596","phase-2-treatment-of-atopic-dermatitis-and-alopecia-areata-with-abrocitinib-in-individuals-with-down-syndrome-100611596","NCT07242638","Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome","Use of Specific JAK Inhibition on Inflammatory Skin and Scalp Diseases in Down Syndrome R61AR084210","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible as study participants:\n\n* Male or female participants who are at least 12 years old, for whom signed informed consent can be provided by parent or legal guardian\u002FLAR prior to participation in any study assessments or procedures.\n* Diagnosis of Trisomy 21 or translocation Down Syndrome.\n* Participant is able to adhere to the study visit schedule and other protocol requirements.\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Week 0\u002FBaseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below: a. Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; or b. Male or female condom (latex condom or non-latex condom NOT made out of natural \\[animal\\] membrane \\[for example, polyurethane\\]).\n* Participant has a history of ≥6 months AD (≥7%BSA) or AA (≥25% scalp involvement). If the participant presents with both conditions, but only one meets the inclusion criteria, then the participant can only be enrolled under that category. If a participant meets inclusion criteria for both conditions at the Baseline visit, then the participant will be enrolled under the AA category as this disease is less prevalent. If the AA category has fulfilled its enrollment target, then the participant will be enrolled in the AD category.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not eligible for randomization as study participants:\n\n* Inability or unwillingness of a participant's parent or legal guardian\u002FLAR to give written informed consent or comply with study protocol.\n* Participant is pregnant or breastfeeding.\n* Participants with AA: A. cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such as traction, cicatricial, pregnancy-related, druginduced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V). B. Participant has a history of AA with no evidence of hair regrowth for ≥7 years since the last episode of hair loss\n* Participant has increased risk of developing venous thromboembolism, e.g. deep vein thrombosis or pulmonary embolism (history of venous thromboembolism, or first-degree relative with unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), that would suggest participant is at increased risk of inherited coagulation disorder (e.g. Factor V Leiden).\n* Participant currently has active forms of other inflammatory skin diseases (eg, psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or AA.\n* Participant was vaccinated or exposed to a live or attenuated vaccine within the 6 weeks prior to Baseline visit, or is expected to be vaccinated or to have household exposure to these vaccines during treatment.\n* Participant has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Week 0\u002FBaseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Infection History: • Participant has an active bacterial, viral, or helminth parasitic infection; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics. • Participant has active chronic or acute skin infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to Baseline or superficial skin infections within 1 week prior to Baseline. • Participant has a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n* Participant has a history of alcohol or substance abuse within 6 months prior to Day 1 that in the opinion of the investigator will preclude participation in the study.\n* Participant with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator.\n* Participant has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease. ANY of the following abnormalities in renal or hepatic tests at screening are exclusionary: Estimated creatinine clearance \\\u003C40 mL\u002Fmin based on the age appropriate calculation, or serum creatinine \\>1.5 times the upper limit of normal (ULN); • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values \\>2 times the ULN; • Total bilirubin ≥1.5 times the ULN; participants with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤ ULN.\n* Participant has active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) prior to Baseline.\n* Participant has positive or indeterminable PPD or QFT result including participants that completed standard tuberculosis therapy prior to Baseline.\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n* Participant has history of adverse systemic or allergic reactions to any component of the study drug or any safety event deemed \"related\" to a JAK inhibitor.\n* Participant has used systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, ritlecitinib, or investigational oral JAK Inhibitors) or ultraviolet (UV) phototherapy with\u002Fwithout Psoralen Ultraviolet A (PUVA) therapy, within 4 weeks prior to the Week 0\u002FBaseline visit.\n* Participant has used systemic monoclonal antibody treatments (such as the IL-4R antagonist dupilumab) within 12 weeks of Baseline visit.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus within 1 week prior to the Week 0\u002FBaseline visit.\n* Participant with Translocation or Mosaic Downs Syndrome.",{"count":464,"type":23},56,[88],"This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and\u002For Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT \\\u003C= 20 for AA) will be kept on this dose, and non-responders based on these definitions, will initiate 200 mg daily for another 12 weeks. All AD and AA patients will be maintained on the respective dose of Abrocitinib from Week 24 through week 60.",[408,29],[469,408,29,470],"Down Syndrome","Abrocitinib","2026-01-29",{"date":473,"type":38},"2026-02-02",{"date":475,"type":38},"2026-01-12",{"date":477,"type":23},"2028-03-03",{"name":340,"class":102},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":327,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":500},"100603191","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-adolescents-with-severe-alopecia-areata-100603191","NCT07133308","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period","Inclusion Criteria:\n\n* Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.\n* Between 12 to \\\u003C18 years of age\n* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.\n* Willing to comply with the study visits and requirements of the study protocol\n\nExclusion Criteria:\n\n* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and\u002For Baseline\n* Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.\n* Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.\n* Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.",{"count":487,"type":23},355,[26],"This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.",[29],"2026-01-27",{"date":493,"type":38},"2026-01-28",{"date":495,"type":38},"2025-08-05",{"date":497,"type":23},"2028-05",{"name":499,"class":45},"Sun Pharmaceutical Industries, Inc.",64,{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":508,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":103},"100541263","combined-microneedling-with-either-1-lactic-acid-solution-or-vitamin-d3-or-triamcinolone-acetonide-in-the-treatment-of-alopecia-areata-100541263","NCT06327581","Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata","Comparative Study of Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata","Inclusion Criteria:\n\n* · Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter).\n\n  * Patients of both sexes\n  * Willing to participate in the study and to sign an informed consent.\n\nExclusion Criteria:\n\n* · Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study\n\n  * Patients with Alopecia totalis, universalis, ophiasis, or sisaipho\n  * Pregnant or lactating females\n  * Patients who had bleeding or coagulation disorders\n  * Immunocompromised patients\n  * Patients with known history of hypersensitivity to vit D\n  * Patients taking vitamin D supplements in the last 6 months.","16 Years",{"count":510,"type":23},88,[403],"Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the scalp, beard area, eyebrows, eyelashes, and less commonly, on other hairy areas of the body (Berker et al., 2010 and James et al., 2011) Alopecia areata is a T-cell-mediated autoimmune disease. There is a complicated interplay between loss of immune privilege in the hair follicle, autoimmune-mediated hair follicle damage, and activation of inflammatory pathways that have been argued to explain the development of this disorder, but the exact pathophysiology of AA remains unknown. Hair follicles are infiltrated by autoreactive CD8 and CD4 T lymphocytes, which attack hair follicle-derived autoantigens while sparing the stem compartment (Rajabi et al., 2018).\n\nAlopecia areata can be treated with topical and\u002For intralesional corticosteroids, which are the treatment of choice. Anthralin, minoxidil, coal tar, and topical immunotherapy are examples of other topical treatments. Systemic immunosuppressants such as cyclosporine, systemic steroids, Janus kinase inhibitors, and methotrexate may be considered in severe resistant cases (lee and lee, 2017).\n\nIntralesional triamcinolone acetonide is preferred in cases of AA , as it is well known as anti-inflammatory and interferes with local immunity of the skin, which helps in the recovery of the disease, but if used in wrong technique or given in a high dose, it might cause all the side effects of corticosteroid, especially skin atrophy (Berker et al., 2010).\n\nLactic acid is a member of alpha-hydroxy acids. It has been used in the treatment of many skin diseases, like AA and vitiligo. Lactic acid stimulates spontaneous secretion of vascular endothelial growth factor (VEGF) by human reconstructed epidermis. VEGF is an angiogenic cytokine involved in angiogenesis and wound healing and stimulates the growth of hair follicles resulting in recovery of AA. Other studies suggest that lactic acid may act through its irritant effect (Al-Tammimy, 2005).\n\nVitamin D interacts with the innate and adaptive immune systems in a variety of ways, the majority of which contribute to its downregulation (Nancy and Yehuda, 2009). It has a powerful effect on T and B lymphocytes, influencing their activation responses (Arnson et al., 2007).\n\nAll cells of the immune system express 1,25-dihydroxyvitamin D3 receptors (VDRs) and are therefore vulnerable to calcitriol-mediated modulation. Vitamin D3 has the ability to influence the migration and maturation of different dendritic cell subtypes and their production of chemokines and cytokines, giving them an immunoregulatory and tolerogenic role (Illescas-Montes et al., 2019) It has been shown that VDRs are highly expressed in the keratinocytes of human hair follicles and the absence of their expression is associated with reduced hair follicle growth and epidermal differentiation. Reduced VDR expression in the hair follicles of affected areas has also been observed in studies of AA patients' scalp (Çerman et al., 2015).\n\nMicroneedling (MN) is a technique that comprises puncturing the skin repeatedly with sterile microneedles (Iriarte et al., 2017). It promotes hair regeneration by triggering stem cells in the hair bulge, which results in the generation of growth factors. It also improves blood circulation to the hair follicles and influences the local immune cells (Chandrashekar et al., 2014). Moreover, combining MN with applied topical drugs facilitates their absorption through the microchannels created within the epidermis (Fertig et al., 2018).",[29],"2026-01-23",{"date":516,"type":38},"2026-01-26",{"date":518,"type":38},"2023-12-15",{"date":520,"type":23},"2026-12-30",{"name":522,"class":291},"Zagazig University",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":281,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":103},"100618824","landscape-demographics-and-treatment-patterns-of-patients-with-immune-mediated-inflammatory-skin-diseases-in-italian-clinical-practice-100618824","NCT07336641","LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice","LANDSCAPE - Demographic Characteristics and Treatment Profiles of Patients Affected by Inflammatory Skin Diseases (Psoriasis, Atopic Dermatitis, Alopecia Areata, Vitiligo, Hidradenitis Suppurativa) in Italian Clinical Practice","LANDSCAPE","Inclusion Criteria:\n\n1. Documented diagnosis of psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.\n2. Age 12 years or older at the first recorded visit.\n3. Eligible for or treated with systemic therapies.\n4. At least one documented visit during January 2016 to December 2025.\n5. No opt-out exercised.\n\nExclusion Criteria:\n\n1. Opt-out exercised.\n2. Medical records with insufficient data.",{"count":532,"type":23},20000,"This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.",[407,408,535,29,355],"Vitiligo",[537,538,539,540,541],"Registry","Real-World Evidence","Treatment Patterns","Dermatology","Italy","2026-01-13",{"date":544,"type":38},"2026-01-15",{"date":546,"type":23},"2026-01",{"date":548,"type":23},"2028-01",{"name":550,"class":102},"Fondazione ISIDE",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":575},"100594734","phase-3-a-study-to-evaluate-the-safety-and-effectiveness-of-upadacitinib-tablets-in-adult-and-adolescent-participants-in-japan-with-alopecia-areata-100594734","NCT07023302","A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata","A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss","Jump Up AA JP","Inclusion Criteria:\n\n* Participant is judged to be in good health as determined by the Principal Investigator, based upon the results of the Screening assessments and medical history.\n* Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score \\>= 25 (\\>= 25% scalp hair loss) at Screening and Baseline.\n* Current episode of AA of less than 8 years.\n\nExclusion Criteria:\n\n* Current diagnosis of primarily diffuse type of AA.\n* Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium.\n* Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.\n* Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral\u002Fintramuscular anti-infectives within 14 days prior to the Baseline Visit.\n* Chronic recurring infection and\u002For active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study.",{"count":560,"type":23},123,[26],"Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants in Japan with severe AA.\n\nUpadacitinib is an approved drug being investigated for the treatment of AA. In Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. In Period B, participants originally randomized to a upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will be re-randomized in 1 of 2 groups receiving upadacitinib. Participants who complete Period B can join Period C and will receive 1 of 2 doses of upadacitinib for up to 52 weeks based on their SALT score. Around 123 adolescent and adult participants with severe AA will be enrolled in the study at approximately 20 sites in Japan.\n\nParticipants will receive oral tablets of either upadacitinib or placebo once daily for up to 104 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after their last study drug dose.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[29],[29,31,565,566],"JUMP-UP","AA","2025-12-18",{"date":569,"type":38},"2025-12-24",{"date":571,"type":38},"2025-06-19",{"date":573,"type":23},"2029-02",{"name":44,"class":45},15,{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":84,"enrollmentInfo":583,"targetDuration":4,"studyType":24,"phases":584,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":597},"100608715","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-fb102-in-patients-with-severe-to-very-severe-alopecia-areata-100608715","NCT07205159","A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","Inclusion Criteria:\n\n* Males aged 18-60 years and females aged 18-75 years at Screening.\n* Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.\n\n  * AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria\n\nExclusion Criteria:\n\n* Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy-induced hair loss, androgenetic alopecia).\n* Other scalp diseases impacting AA assessment (e.g., psoriasis, dermatitis, tinea capitis).\n* Active systemic diseases causing hair loss (e.g., lupus, thyroiditis, systemic sclerosis, lichen planus, syphilis).\n\nNote: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria",{"count":5,"type":23},[585],"PHASE1","This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).",[29],"2025-11-17",{"date":590,"type":38},"2025-11-20",{"date":592,"type":38},"2025-10-23",{"date":594,"type":23},"2027-03-10",{"name":596,"class":45},"Forte Biosciences, Inc.",6,{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":4,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":604,"phases":4,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":614,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":615,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":617,"locationsCount":4},"100479405","pre-approval-single-patient-expanded-access-for-ritlecitinib-pf-06651600-100479405","NCT05522556","Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)","Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.","EXPANDED_ACCESS","Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.",[29],[608,227,609,610,379,611,612,613,157],"Alopecia Areata (AA)","Patchy AA","Alopecia Universalis (AU)","Ophiasis","Eyelash Loss","Eyebrow Loss","AVAILABLE",{"date":616,"type":38},"2025-11-18",{"name":211,"class":45}]